Education
About Us
Working with TipRanks
Follow Us
Polynovo Limited (AU:PNV)
ASX:PNV
Top Page
Polynovo
(Sydney:PNV)
Select Model
Select Model
Rating:62Neutral
Price Target:
AU$1.00
▲(11.11% Upside)
Action:ReiteratedDate:02/20/26
The score is driven primarily by solid fundamental performance (strong growth, very high gross margins, and a healthy balance sheet) and a constructive earnings update with improving cash flow and clear milestones. This is tempered by weak technical trend signals and an expensive valuation (high P/E, no yield), which increase sensitivity to execution and cash flow follow-through.
Positive Factors
Commercial growth & U.S. account expansion
Sustained double‑digit group and U.S. revenue growth and steady new hospital account additions show durable commercial adoption. A broadened account base and >80 U.S. reps reduce single‑customer risk and support recurring procedure volumes and predictable hospital procurement demand.
Very high gross margins & rising profitability
Exceptionally high gross margins indicate strong product economics from the NovoSorb platform, enabling significant operating leverage. Improving adjusted EBITDA demonstrates scalable margin conversion as sales grow, supporting reinvestment in commercial and regulatory activities without eroding unit economics.
Manufacturing scale‑up and regulatory progress
A validated facility with ~5x capacity materially improves supply scalability and lowers unit risk for multi‑SKU growth. Concurrent PMA progress with BARDA builds a regulatory moat for key indications, enabling expanded hospital adoption and stable revenue channels across institutional markets.
Negative Factors
Weak cash conversion & FCF dynamics
Despite revenue and margin strength, weak free cash flow conversion and low OCF-to-net‑income create funding sensitivity. Persistent negative FCF growth can constrain reinvestment, extend payback on commercial expansion, and increase reliance on equity or debt during scale‑up phases.
Outpatient reimbursement and regulatory uncertainty
Outpatient channels represent meaningful incremental market opportunity, but exigent CMS coverage requiring RCT evidence delays monetization. Uncertain timing and trial requirements mean outpatient revenue is not guaranteed, slowing diversification away from hospital and burn‑centric volumes.
Lumpy demand and limited near‑term visibility
A business exposed to episodic burn volumes and seasonal case variability complicates forecasting and capacity planning. Combined with no formal guidance, this raises execution risk for scaling manufacturing and commercial spend, making outcome timing and cash flow less predictable.
Polynovo (PNV) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$607.94M
Dividend YieldN/A
Average Volume (3M)1.48M
Price to Earnings (P/E)70799.0
Beta (1Y)2.04
Revenue Growth23.31%
EPS Growth151.32%
CountryAU
Employees282
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.00
Shares Outstanding690,843,000
10 Day Avg. Volume1,478,953
30 Day Avg. Volume1,476,427
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)9.95
Price to Sales (P/S)6.51
P/FCF Ratio-76.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.74Price Target Upside93.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$153.39M
Polynovo Business Overview & Revenue Model
Company DescriptionPolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
How the Company Makes MoneyPolynovo generates revenue primarily through the sale of its medical products, particularly its NovoSorb line, which is marketed to hospitals, clinics, and healthcare providers. The company adopts a direct sales model and partners with distributors to reach a wider customer base. Key revenue streams include sales of dermal scaffolds for surgical applications, advanced wound care products, and potential licensing agreements for its technology. Additionally, Polynovo may benefit from partnerships with other medical technology firms and healthcare providers, enhancing its market presence and driving growth through collaborative efforts in research, development, and distribution.
Polynovo Earnings Call Summary
Earnings Call Date:Feb 20, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Aug 21, 2026
Earnings Call Sentiment Positive
The call presents a predominantly positive operational and commercial picture: double‑digit revenue growth across major regions (group +26%, U.S. +25.3%, RoW +28.3%), rapid MTX adoption (~+193%), improved cash flow (+$9.0M) and a strong clinical evidence base (348 studies). Key strategic catalysts (PMA submission, SynPath outpatient pathway, expanded manufacturing capacity, recruitment of a Chief Scientific Officer) provide clear upside. Short‑term headwinds include a timing‑related manufacturing variance (~$3.6–3.7M) from planned slowdowns, an R&D lab fire asset write‑off (insured), FX translation losses, and reimbursement/regulatory uncertainty for outpatient CMS coverage which may require an RCT. Management frames several negatives as one‑offs or timing issues and expects margin and free cash flow improvement in H2. Overall, highlights materially outweigh the lowlights.Q2-2026 Updates
Positive Updates
Strong Group Revenue Growth
Group NovoSorb product sales were $68.2 million, up 26% year‑on‑year (+$14.1 million), indicating solid momentum into the second half.
U.S. Performance and Account Expansion
U.S. sales were $51.7 million, up 25.3% YoY; added 95 new hospital accounts during the period and now have over 800 hospital accounts. U.S. business is profitable and generating strong cash flows.
International Growth (Rest of World)
Rest of world sales were $16.5 million, up 28.3% YoY. Notable market growth: Australia +52%, Canada +50.8%, Germany +28.3%, Turkey +91.3%, India +49.1%. Rest of world now represents ~24% of global sales.
Rapid Adoption of NovoSorb MTX
NovoSorb MTX sales were ~$6.0–6.2 million (group/U.S. figures noted), up ~193–195% YoY. MTX is in use in over 240 U.S. accounts and is expanding indications beyond burns.
Channel and Contract Momentum in U.S.
Contracted U.S. channels showed strong growth: GPO sales +37.8%, IDM sales +34.1%, federal account sales +87.2%. Contracted accounts represent 39.9% of total U.S. sales.
Improved Cash Flow and Balance Sheet
Cash on hand $29.2 million. Cash flow from operations improved to +$9.0 million (versus a $12.5 million outflow prior period). Debtor days in the U.S. reduced from >90 to 56 days.
Profitability Underlying Improvement (Adjusted EBITDA)
Adjusted EBITDA was $4.7 million, up 82% YoY after adjusting for significant items (R&D lab fire, unrealized FX translation). Management notes underlying EBITDA momentum when timing one-offs excluded.
Manufacturing Capacity and Facility Completion
New manufacturing facility construction completed (validation ongoing). Management estimates roughly ~5x previous capacity, providing flexibility for multiple SKUs and scale; remaining CapEx ~$2.2 million to be paid in H2.
Regulatory and Clinical Progress (PMA & Evidence Base)
PMA submission for on‑label indication in full‑thickness burns is in final stages (targeting FY‑end) in partnership with BARDA. Clinical evidence base strong: 348 peer‑reviewed real‑world studies (65 translate to outpatient use; 5 in diabetic limb salvage). RCT data expected in 6–12 months for diabetic limb salvage.
Strategic Commercial Initiatives for Outpatient Market
Responding to U.S. outpatient reimbursement changes with SynPath bilayer brand (existing HCPCS code) and monolayer matrix code expected later in the year; inventory and product sizes being prepared for outpatient procedures. Outpatient upside is treated as incremental to current forecasts.
Operational Improvements and Talent Additions
Key leadership hires/promotions: new CEO (Bruce Peatey), new Company Secretary & General Counsel (Amy Demediuk), promotion of Allison Myers to Chief Quality & Regulatory Affairs Officer; active recruitment of Chief Scientific Officer, Market Access Director, and Senior Product Manager in U.S.
Negative Updates
Temporary Manufacturing Output Reduction and Unfavorable Variance
Management intentionally slowed manufacturing to complete validation and preparation for PMA/FDA audit, producing an unfavorable manufacturing variance of ~$3.6–3.7 million for the half and reducing production recovery. Half‑year gross margin was 88.8% as a result (management expects >90% for full year once output ramps).
R&D Lab Fire and Asset Write‑Off
R&D lab fire resulted in a ~$4.4 million asset write‑off (offset by a $4.6 million interim insurance claim recorded in other income). Investigations ongoing; rebuild costs are insured but there was disruption and a minor rebuild is required.
FX Headwind and Unrealized Translation Loss
Strong Australian dollar created an unrealized FX loss of $0.76 million this period (compared with a $4.6 million unrealized gain in the prior period), representing a headwind to reported results and margins.
Timing/Revenue Impact from BARDA Trial Nearing Completion
BARDA revenue declined as the pivotal burns trial nears completion (trial costs reduced accordingly), which reduced R&D revenue recognized in the period compared with prior periods.
Regulatory and Reimbursement Uncertainty for Outpatient Channel
CMS outpatient policy changes create uncertainty; management anticipates a need for a dedicated RCT to support CMS reimbursement in office settings (DFU and VLU). Timing of CMS decisions is unclear and outpatient revenue is treated as upside rather than baked into forecasts.
Seasonality / Short‑term Softness and Market Variability
Noted softer activity in November (fewer large burn cases and seasonal impacts like Thanksgiving) causing quarter‑to‑quarter variability. Burn market exposure remains lumpy and creates forecasting unpredictability.
No Formal Financial Guidance
Management confirmed it will not provide formal guidance in the near term due to growth phase, variability in burn volumes and evolving opportunities; this may limit near‑term visibility for investors.
Tender Complexity and Slower Ramp in India
India market development has been slow due to complex tender processes; while growth is now occurring, progress has taken longer than initially expected and will build over time.
One‑off Costs and Higher Employee‑Related Expenses
Employee‑related costs rose 12.2% YoY (including ~$0.7 million restructuring costs). Headcount increased historically from 254 to ~302 and remains an area of elevated operating cost as organization scales.
Company Guidance
Management provided no formal earnings guidance but gave clear directional guidance and milestones: group NovoSorb sales were $68.2m (+26% YoY, +$14.1m), driven by the U.S. at $51.7m (+25.3%) and Rest of World $16.5m (+28.3%); MTX sales were $6.0m (+193%) and now in >240 U.S. accounts, total customer accounts exceed 800 after adding 95 new hospital accounts, and the U.S. commercial team is >80 reps. Key financials/targets include adjusted EBITDA $4.7m (+82%), H1 gross margin 88.8% with management expecting >90% for FY‑26 after a $3.7m one‑off manufacturing variance, cash on hand $29.2m, operating cash flow $9m (vs prior period -$12.5m), debtors days improved to 56 (from >90), CapEx paid $10.8m with $2.2m remaining, and the new Port Melbourne facility (~5x prior capacity) being qualified for production (firing up from July). Clinical and market milestones: PMA submission for on‑label full‑thickness burns on track for FY‑end (BARDA partnered), 348 peer‑reviewed studies (65 relevant to outpatient, 5 in diabetic limb salvage) with RCT data due in 6–12 months and a planned RCT for CMS reimbursement, SynPath outpatient pathway leveraging an existing HCPCS code (monolayer code expected later this year) with new outpatient sizes available this half, and planned hires (Market Access Director, Senior Product Manager, CSO) to accelerate outpatient and international expansion; management reiterated outpatient contribution is upside and, given burn variability, they will not provide formal near‑term guidance.Polynovo Financial Statement Overview
Summary
Strong revenue growth (+10.09%) and exceptionally high gross margin (95.92%) support the score, alongside a solid balance sheet with low leverage (debt-to-equity 0.21) and improved ROE (15.87%). The main offset is weaker cash conversion, including negative free cash flow growth (-34.06%) and low operating cash flow to net income (0.11).Income Statement
Polynovo has demonstrated strong revenue growth with a 10.09% increase in the latest year, indicating a positive trajectory. The gross profit margin is exceptionally high at 95.92%, showcasing efficient cost management. However, the net profit margin, while improved, remains moderate at 10.38%, suggesting room for further profitability enhancement. The EBIT and EBITDA margins have improved significantly, reflecting better operational efficiency.75
Positive
Balance Sheet
The company maintains a healthy debt-to-equity ratio of 0.21, indicating prudent leverage management. Return on equity has improved to 15.87%, reflecting enhanced profitability for shareholders. The equity ratio is stable, suggesting a solid capital structure. However, the company should continue to monitor its debt levels to maintain financial stability.70
Positive
Cash Flow
Polynovo's cash flow performance shows challenges, with a negative free cash flow growth rate of -34.06%, indicating cash flow management issues. The operating cash flow to net income ratio is low at 0.11, suggesting limited cash generation from operations relative to net income. The free cash flow to net income ratio is negative, highlighting a need for improved cash flow management.60
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 137.93M | 127.24M | 103.19M | 65.24M | 41.44M | 29.16M |
| Gross Profit | 44.57M | 122.05M | 97.71M | 19.33M | 16.23M | 7.83M |
| EBITDA | 7.12M | 10.45M | 4.59M | -2.71M | 658.24K | -3.41M |
| Net Income | 9.88M | 13.21M | 5.26M | -4.92M | -1.19M | -4.61M |
Balance Sheet | ||||||
| Total Assets | 123.37M | 127.41M | 108.72M | 92.62M | 34.97M | 38.34M |
| Cash, Cash Equivalents and Short-Term Investments | 29.26M | 33.59M | 45.96M | 46.90M | 6.15M | 7.74M |
| Total Debt | 31.74M | 17.14M | 15.38M | 16.04M | 10.99M | 10.00M |
| Total Liabilities | 40.23M | 44.15M | 36.60M | 27.24M | 17.26M | 15.99M |
| Stockholders Equity | 83.14M | 83.26M | 72.12M | 65.38M | 17.72M | 22.35M |
Cash Flow | ||||||
| Free Cash Flow | 5.37M | -10.78M | 786.00K | -7.46M | -2.55M | -3.82M |
| Operating Cash Flow | 24.95M | 3.15M | 3.68M | -5.93M | -2.06M | -248.74K |
| Investing Cash Flow | -19.58M | -13.22M | -1.49M | -1.53M | 5.86M | -3.57M |
| Financing Cash Flow | -1.98M | -2.39M | -3.17M | 48.06M | -5.39M | -70.37K |
Polynovo Technical Analysis
Negative
0.90
Price Trends
1.08
Negative
1.17
Negative
1.23
Negative
Market Momentum
-0.04
Negative
38.56
Neutral
32.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PNV, the sentiment is Negative. The current price of 0.9 is below the 20-day moving average (MA) of 0.95, below the 50-day MA of 1.08, and below the 200-day MA of 1.23, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 38.56 is Neutral, neither overbought nor oversold. The STOCH value of 32.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PNV.
Polynovo Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | AU$607.94M | 70,799.02 | 16.49% | ― | 23.31% | 151.32% | |
56 Neutral | AU$210.74M | -47.06 | -2.01% | ― | 16.93% | 76.47% | |
55 Neutral | AU$146.36M | 52.88 | -7.26% | ― | 21.65% | 81.40% | |
53 Neutral | AU$2.32B | -3.16 | -44.49% | ― | 55.91% | 22.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$97.09M | -6.27 | -31.98% | ― | 34.20% | -23.90% | |
44 Neutral | AU$159.85M | -10.00 | -70.55% | ― | ― | -257.32% |
* Healthcare Sector Average
AU:PNV
Polynovo
0.88
-0.52
-37.14%
AU:SOM
Somnomed Limited
0.67
0.11
20.72%
AU:CYC
Cyclopharm Limited
0.76
-0.64
-46.07%
AU:ARX
Aroa Biosurgery Ltd
0.63
0.14
27.55%
AU:EMV
EMvision Medical Devices Ltd.
1.72
-0.08
-4.44%
AU:4DX
4DMedical Ltd
4.05
3.67
965.79%
Polynovo Corporate Events
PolyNovo Sets Webcast to Present H1 FY26 Results
Feb 20, 2026
PolyNovo has released an announcement regarding its H1 FY26 financial results, indicating that a detailed presentation will be provided via a scheduled webcast. The event will feature updates from the chair, CEO and CFO, including financial performance highlights and an analyst Q&A session, signalling the company’s intent to engage closely with investors and stakeholders around its interim performance.
While the announcement itself contains minimal quantitative detail, its structured agenda underscores the importance of this half-year update in communicating strategic and financial progress. The inclusion of a dedicated Q&A suggests PolyNovo is aiming to enhance transparency, address market expectations and potentially shape investor sentiment around its trajectory in the medical technology market.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$0.95 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo lifts half-year sales and capacity as new CEO targets next growth phase
Feb 20, 2026
PolyNovo reported half-year FY26 group sales of A$68.2 million, up 26% year-on-year, with U.S. revenue rising 25.3% and NovoSorb MTX sales nearly tripling, while total revenue including BARDA reached A$75 million. Despite flat net profit, adjusted EBITDA rose 82%, reflecting improving underlying performance even as BARDA revenue declined following completion of a pivotal burns trial.
Operationally, the company completed construction of an additional manufacturing facility in Port Melbourne and strengthened its leadership with the appointment of CEO Bruce Peatey and Company Secretary and General Counsel Amy Demediuk. PolyNovo also launched an enhanced online investor hub to improve shareholder communication, positioning the business for its next growth phase amid strong clinical demand and more favourable reimbursement trends.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$0.95 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Expands Balkan Reach With New NovoSorb Distributor
Feb 1, 2026
PolyNovo has appointed Arbor Vitae International LLC as its distributor for eight Balkan countries, extending its European commercial reach to an additional 22 million people through a cost-effective distribution model. The partnership, which capitalises on Arbor Vitae’s established network of key opinion leaders and its role in recent high-profile burn and trauma cases in the region, is expected to deepen surgeon adoption of NovoSorb products beyond acute burns into broader trauma and reconstructive indications, supporting PolyNovo’s capital-light European expansion strategy and strengthening its competitive positioning in advanced wound care.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Delivers Strong 1H26 Growth, Boosts Cash and Capacity as NovoSorb Adoption Accelerates
Jan 18, 2026
PolyNovo reported unaudited first-half FY26 group sales of A$68.2 million, a 26% year-on-year increase driven by strong U.S. performance and rapid growth in NovoSorb MTX, while Rest of World sales also rose sharply, offsetting an expected decline in BARDA revenue as a pivotal burn trial concluded. Total revenue including BARDA reached A$70.4 million, cash flow from operations swung to a A$9.5 million inflow, and the new manufacturing facility was completed on time and budget, underpinning future capacity, as the company advances a U.S. pre-market approval submission for full-thickness burns, seeks expanded CMS reimbursement and coding for its products, and navigates evolving U.S. outpatient skin substitute policies while meeting heightened European demand following recent mass-casualty burn events.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.03 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Appoints New Company Secretary and General Counsel
Dec 8, 2025
PolyNovo Limited has appointed Amy Demediuk as Company Secretary and General Counsel, effective February 2026. Ms. Demediuk brings extensive legal and compliance experience from her previous roles at CSL, enhancing PolyNovo’s leadership team as it seeks to continue its growth trajectory. Her appointment is expected to add significant value to the company’s operations and stakeholder engagement.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$1.62 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.